Multifunctional nanoparticles for co-delivery of paclitaxel and carboplatin against ovarian cancer by inactivating the JMJD3-HER2 axis

C60(OH)22: a potential histone deacetylase inhibitor with anti-angiogenic activity

(2016) Chengdu Sun et al.   Nanoscale

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer

(2016) L Castagnoli et al.   ONCOGENE

Polymeric nanoparticles for colon cancer therapy: overview and perspectives

(2016) Xinru You et al.   Journal of Materials Chemistry B

Paclitaxel-loaded phosphonated calixarene nanovesicles as a modular drug delivery platform

(2016) Jingxin Mo et al.   Scientific Reports

Targeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticles

(2016) Alexandra Rodzinski et al.   Scientific Reports

Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug

(2015) Miles A. Miller et al.   Nature Communications

Shear induced carboplatin binding within the cavity of a phospholipid mimic for increased anticancer efficacy

(2015) Jingxin Mo et al.   Scientific Reports

Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer

(2015) Zachary C. Dobbin et al.   Oncotarget

Development and validation of a LC/TOF MS method for the determination of carboplatin and paclitaxel in nanovesicles

(2014) Jingxin Mo et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Critical role of histone demethylase Jmjd3 in the regulation of CD4+ T-cell differentiation

(2014) Qingtian Li et al.   Nature Communications

Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy

(2014) Alexey Goltsov et al.   Cells

Systemic Delivery of microRNA-34a for Cancer Stem Cell Therapy

(2013) Sanjun Shi et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Epigenetics in focus: Pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents

(2013) Valeria Santini et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap

(2013) Matthew J. Ellis et al.   Cancer Discovery

Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family

(2013) Anton Arkhipov et al.   eLife

Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo

(2011) Shanta Dhar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

(2011) A. Chakrabarty et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

(2009) Noriyuki Katsumata et al.   LANCET